The Crystalens AO has prolate aspheric surfaces and is designed to be free of spherical aberration and is intended to improve retinal image quality without compromising depth of field, according to the release.
Crystalens is the only FDA-approved accommodating intraocular lens. Unlike a standard cataract replacement lens, Crystalens is designed to not only eliminate a patient’s cataract but to improve the patient’s range of vision.
Although aspheric optics traditionally reduce field of vision because they have negative spherical aberration, the Crystalens AO does not reduce field of vision because it provides zero spherical aberration, according to the release.
The Crystalens AO is comprised of proprietary biosil silicone and has a thin and uninterrupted barrier edge. It will be inserted using the CI-28 injector in a controlled manner through an un-enlarged phaco incision.
Read Bausch & Lomb’s release on Crystalens AO.
